FML® Ointment
Fluorometholone 0.1% · ophthalmic ointment
Steroid
Approved uses
Corticosteroid-responsive inflammation of the conjunctiva, cornea, and anterior segment
Approximately a 1/2 inch ribbon 1 to 3 times daily; may be increased to every 4 hours during the initial 24 to 48 hours
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella.
- Mycobacterial ocular infection.
- Fungal diseases of ocular structures.
- Known or suspected hypersensitivity to any ingredient of the preparation or to other corticosteroids.
0.1% ointment, 3.5 g tube.
Corticosteroid; there is no generally accepted explanation for its ocular mechanism, but corticosteroids are thought to induce phospholipase A2 inhibitory proteins (lipocortins), which are postulated to control synthesis of prostaglandins and leukotrienes by inhibiting release of their common precursor, arachidonic acid. Inhibits edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation, and probably delays or slows healing.
Warnings & Precautions
- Increased intraocular pressure: Prolonged use of corticosteroids may increase intraocular pressure in susceptible individuals, resulting in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation.
- Secondary ocular infections: Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections.
- Steroid IOP response: In steroid-responders, fluorometholone took longer on average than dexamethasone phosphate to produce a rise in IOP (a significant difference), but in a small percentage of individuals a significant rise occurred within one week; the ultimate magnitude of the rise was equivalent for both drugs.
- IOP monitoring: If the product is used 10 days or longer, routinely monitor intraocular pressure even though it may be difficult in children and uncooperative patients; use with caution in the presence of glaucoma and check intraocular pressure frequently.
- Corneal healing: Ophthalmic ointments may retard corneal healing.
- Corneal or scleral thinning: Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning, and use in the presence of thin corneal or scleral tissue may lead to perforation.
- Acute purulent infection: May be masked or its activity enhanced by corticosteroid.
- Delayed healing and bleb formation: The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.
- Viral ocular infection: Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex); use in patients with a history of herpes simplex requires great caution, and frequent slit lamp microscopy is recommended.
- Fungal infections of the cornea: These are particularly prone to develop coincidentally with long-term local corticosteroid applications; suspect fungal invasion in any persistent corneal ulceration where a corticosteroid has been used or is in use, and take fungal cultures when appropriate.
- Examination with magnification: The initial prescription and renewal beyond 8 grams should follow examination with magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining; re-evaluate the patient if signs and symptoms fail to improve after two days.
- Persistent inflammation or pain: If inflammation or pain persists longer than 48 hours or becomes aggravated, advise the patient to discontinue use and consult a physician.
- Contamination: Avoid touching the tube tip to eyelids or any other surface; use of the tube by more than one person may spread infection.
Common Side Effects
Adverse reactions, in decreasing order of frequency, include elevated IOP with possible glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation, and ptosis have occasionally been reported. Other reported events include allergic reactions, foreign body sensation, eyelid erythema and edema, eye discharge, eye pain, eye pruritus, increased lacrimation, ocular irritation, rash, taste perversion, blurry vision, and visual field defect. Secondary bacterial, fungal, and viral infection has occurred, and acute anterior uveitis and perforation of the globe have been reported. Systemic effects are extremely uncommon; rare systemic hypercorticoidism followed topical dermatologic steroids applied to the skin.
Pregnancy: Embryocidal and teratogenic in rabbits at low multiples of the human ocular dose, with dose-related fetal loss, cleft palate, deformed rib cage, anomalous limbs, encephalocele, craniorachischisis, and spina bifida after ocular dosing on gestation days 6 to 18; no adequate human studies; use only if benefit justifies fetal risk.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth or interfere with endogenous corticosteroid production; whether topical ocular dosing yields detectable milk levels is unknown; decide between discontinuing nursing and discontinuing the drug.
Safety and effectiveness in infants below 2 years of age not established.